Lumibird (LBIRD) Q2 2025 TU earnings summary

Executive summary

• Consolidated H1 2025 revenue reached €106.8 million, up 9.0% year-over-year, with both Photonics and Medical divisions contributing to growth.

• Photonics division revenue rose 8.6% in H1, driven by Defense/Space activities, while Medical division grew 9.4%, supported by new marketing authorizations.

• Optimized production management and a strong backlog position both divisions for further EBITDA improvement.

Financial highlights

• Q1 2025 revenue: €49.4 million (+12.4% year-over-year); Q2 2025 revenue: €57.4 million (+6.3% year-over-year).

• H1 2025 Photonics revenue: €51.3 million (+8.6%); Medical revenue: €55.6 million (+9.4%).

• Diagnostic equipment accounted for 23.5% and laser treatment products for 76.5% of Medical sales.

Outlook and guidance

• Strong backlog at end of June, especially in Defense/Space and Medtech, supports positive outlook.

• Significant EBITDA improvement anticipated for H1 2025 in both divisions, with Photonics benefiting from Defense growth and Medical from margin optimization.